RT Journal Article
T1 Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
A1 Kaaks, Rudolf
A1 Fortner, Renée Turzanski
A1 Hüsing, Anika
A1 Barrdahl, Myrto
A1 Hopper, Marika
A1 Johnson, Theron
A1 Tjønneland, Anne
A1 Hansen, Louise
A1 Overvad, Kim
A1 Fournier, Agnès
A1 Boutron-Ruault, Marie-Christine
A1 Kvaskoff, Marina
A1 Dossus, Laure
A1 Johansson, Mattias
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Benetou, Vassiliki
A1 La Vecchia, Carlo
A1 Sieri, Sabina
A1 Mattiello, Amalia
A1 Palli, Domenico
A1 Tumino, Rosario
A1 Matullo, Giuseppe
A1 Onland-Moret, N Charlotte
A1 Gram, Inger T
A1 Weiderpass, Elisabete
A1 Sanchez-Perez, Maria-Jose
A1 Navarro Sanchez, Carmen
A1 Duell, Eric J
A1 Ardanaz, Eva
A1 Larranaga, Nerea
A1 Lundin, Eva
A1 Idahl, Annika
A1 Jirström, Karin
A1 Nodin, Björn
A1 Travis, Ruth C
A1 Riboli, Elio
A1 Merritt, Melissa
A1 Aune, Dagfinn
A1 Terry, Kathryn
A1 Cramer, Daniel W
A1 Anderson, Karen S
K1 antibodies
K1 early detection
K1 prospective validation
AB Immuno-proteomic screening has identified several tumor-associated autoantibodies (AAb) that may have diagnostic capacity for invasive epithelial ovarian cancer, with AAbs to P53 proteins and cancer-testis antigens (CTAGs) as prominent examples. However, the early detection potential of these AAbs has been insufficiently explored in prospective studies. We performed ELISA measurements of AAbs to CTAG1A, CTAG2, P53 and NUDT11 proteins, for 194 patients with ovarian cancer and 705 matched controls from the European EPIC cohort, using serum samples collected up to 36 months prior to diagnosis under usual care. CA125 was measured using electrochemo-luminiscence. Diagnostic discrimination statistics were calculated by strata of lead-time between blood collection and diagnosis. With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95% CI 0.08-0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10-0.44] for P53 (0.33 [0.11-0.68] for high-grade serous tumors). However, at longer lead-times, the ability of these AAb markers to distinguish future ovarian cancer cases from controls declined rapidly; at lead times >1 year, SE98 estimates were close to zero (all invasive cases, range: 0.01-0.11). Compared to CA125 alone, combined logistic regression scores of AAbs and CA125 did not improve detection sensitivity at equal level of specificity. The added value of these selected AAbs as markers for ovarian cancer beyond CA125 for early detection is therefore limited.
YR 2018
FD 2018-03-08
LK http://hdl.handle.net/10668/12173
UL http://hdl.handle.net/10668/12173
LA en
DS RISalud
RD Apr 10, 2025